{"organizations": [], "uuid": "7d180e0130cf8c017b92aca9111aea996b943877", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180123.html", "section_title": "Archive News &amp; Video for Tuesday, 23 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-genfit-official-launch-of-nash-ped/brief-genfit-official-launch-of-nash-pediatric-program-in-us-idUSASM000IDZ", "country": "US", "domain_rank": 408, "title": "BRIEF-Genfit: Official Launch Of NASH Pediatric Program In US", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-01-23T15:47:00.000+02:00", "replies_count": 0, "uuid": "7d180e0130cf8c017b92aca9111aea996b943877"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-genfit-official-launch-of-nash-ped/brief-genfit-official-launch-of-nash-pediatric-program-in-us-idUSASM000IDZ", "ord_in_thread": 0, "title": "BRIEF-Genfit: Official Launch Of NASH Pediatric Program In US", "locations": [], "entities": {"persons": [{"name": "genfit", "sentiment": "negative"}], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "nash", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 23 (Reuters) - GENFIT SA:\n* REG-GENFIT: OFFICIAL LAUNCH OF THE NASH PEDIATRIC PROGRAM, FOLLOWING PIP AND PSP AGREEMENT BY EMA AND FDA\n* ‍FDA AGREES WITH ELAFIBRANOR‘S INITIAL PSP FOR LAUNCH OF NASH PEDIATRIC CLINICAL TRIAL IN US\n* ‍PHASE 2B DATA SUPPORTIVE OF ELAFIBRANOR‘S POTENTIAL BENEFIT IN NASH PEDIATRIC POPULATION​\n* PSP AGREEMENT BY FDA CONSISTENT WITH PIP (PEDIATRIC INVESTIGATION PLAN) AGREEMENT BY EMA (EUROPEAN MEDICINES AGENCY)\n* ‍DOSE RANGING STUDY TO START IN COMING WEEKS, ON YOUNG NASH PATIENTS LIVING IN US (8-17 YEARS OLD)​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-23T15:47:00.000+02:00", "crawled": "2018-01-24T15:52:57.000+02:00", "highlightTitle": ""}